Ella X. Du
About
Ella X. Du is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics.
According to data from OpenAlex, Ella X. Du has authored 48 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Economics and Econometrics. Recurrent topics in Ella X. Du's work include Economic and Financial Impacts of Cancer (9 papers), CAR-T cell therapy research (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ella X. Du is often cited by papers focused on Economic and Financial Impacts of Cancer (9 papers), CAR-T cell therapy research (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ella X. Du collaborates with scholars based in United States, China and United Kingdom. Ella X. Du's co-authors include Ahmed M. Soliman, Hongbo Yang, Craig A. Winkel, Caroline Kelley, Eric Q. Wu, Keith A. Betts, Sneha S. Kelkar, Jipan Xie, Mahesh Fuldeore and Patrick Tang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Obstetrics and Gynecology.
In The Last Decade
Ella X. Du
46 papers receiving 666 citations
Peers
Ella X. Du
Cesare Romagnolo Italy
Élodie Chantalat France
Lorenzo Aguzzoli Italy
Giulia Mariani Italy
Anette Kjærbye‐Thygesen Denmark
Ramon McGehee United States
David E Tourgeman United States
Martin Sillem Germany
Anne Goverde Netherlands
Lise Duranteau France
Citations per year, relative to Ella X. Du Ella X. Du (= 1×)
peers
Cesare Romagnolo
Countries citing papers authored by Ella X. Du
Since
Specialization
Citations
This map shows the geographic impact of Ella X. Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella X. Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella X. Du more than expected).
Fields of papers citing papers by Ella X. Du
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ella X. Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella X. Du. The network helps show where Ella X. Du may publish in the future.
Co-authorship network of co-authors of Ella X. Du
This figure shows the co-authorship network connecting the top 25 collaborators of Ella X. Du. A scholar is included among the top collaborators of Ella X. Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ella X. Du. Ella X. Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lee, Scott D., Keith A. Betts, Ella X. Du, et al.. (2024). Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn s & Colitis 360. 6(2). otae026–otae026.
2.
Rimel, B.J., Dana M. Chase, Armen A. Ghazarian, et al.. (2024). Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting. Gynecologic Oncology Reports. 51. 101332–101332.
3.
Moser, Justin C., Shailender Bhatia, Asim Amin, et al.. (2024). Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data. Cancer Immunology Immunotherapy. 73(7). 116–116.
4.
Chase, Dana M., B.J. Rimel, Armen A. Ghazarian, et al.. (2023). Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200). Gynecologic Oncology. 176. S257–S257.
5.
Weber, Jeffrey S., Ella X. Du, Yan Chen, et al.. (2022). Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer Immunology Immunotherapy. 72(4). 945–954.
6.
McGregor, Bradley A., Daniel M. Geynisman, Mauricio Burotto, et al.. (2022). Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. The Oncologist. 28(1). 72–79.
7.
Li, Jingxian, et al.. (2022). A risk signature based on necroptotic-process-related genes predicts prognosis and immune therapy response in kidney cell carcinoma. Frontiers in Immunology. 13. 922929–922929.
8.
McGregor, Bradley A., Daniel M. Geynisman, Mauricio Burotto, et al.. (2021). PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC). Value in Health. 24. S28–S29.
9.
Geynisman, Daniel M., Bradley A. McGregor, Mauricio Burotto, et al.. (2021). PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC). Value in Health. 24. S36–S36.
10.
Pope, Janet, Namita Tundia, Ella X. Du, et al.. (2020). Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in Therapy. 37(5). 2356–2372.
11.
Moshyk, Andriy, et al.. (2019). PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL. Value in Health. 22. S483–S483.
12.
Thuresson, Per-Olof, et al.. (2019). PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?. Value in Health. 22. S482–S482.
13.
Malcolm, Bill, et al.. (2019). PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN. Value in Health. 22. S458–S458.
14.
Soliman, Ahmed M., et al.. (2017). Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. Journal of Women s Health. 26(6). 644–654.
15.
Betts, Keith A., et al.. (2017). Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. Journal of Stroke and Cerebrovascular Diseases. 26(9). 1996–2003.
16.
Li, Nanxin, Jennifer Pocoski, Rajeev Ayyagari, et al.. (2016). Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. Journal of Blood Medicine. Volume 7. 129–137.
17.
Pocoski, Jennifer, Peggy L. Lin, Sneha S. Kelkar, et al.. (2014). Associations Between Joint Damage and Quality of Life Among Patients with Severe Hemophilia a in the 3-Year Spinart Trial. Blood. 124(21). 200–200.
18.
Soliman, Ahmed M., Mahesh Fuldeore, Hongbo Yang, et al.. (2014). Treatment patterns among US women diagnosed with endometriosis: a retrospective claims analyses pre- and post-diagnosis. Fertility and Sterility. 102(3). e290–e290.
19.
Wu, E.Q., et al.. (2014). Costs Of Venous Thromboembolism (Vte) Among Hospitalized Patients In China. Value in Health. 17(3). A109–A109.
20.
Fuldeore, Mahesh, Hongbo Yang, Ella X. Du, et al.. (2014). Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fertility and Sterility. 103(1). 163–171.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cesare Romagnolo Breakdown of academic impact, for papers by Élodie Chantalat Breakdown of academic impact, for papers by Lorenzo Aguzzoli Breakdown of academic impact, for papers by Giulia Mariani Breakdown of academic impact, for papers by Anette Kjærbye‐Thygesen Breakdown of academic impact, for papers by Ramon McGehee Breakdown of academic impact, for papers by David E Tourgeman Breakdown of academic impact, for papers by Martin Sillem Breakdown of academic impact, for papers by Anne Goverde Breakdown of academic impact, for papers by Lise Duranteau